Insider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 14,905 Shares of Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 14,905 shares of Journey Medical stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.01, for a total transaction of $74,674.05. Following the completion of the transaction, the chief executive officer now owns 2,052,418 shares in the company, valued at approximately $10,282,614.18. The trade was a 0.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Claude Maraoui also recently made the following trade(s):

• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Trading Down 2.7 %

NASDAQ:DERM traded down $0.14 during trading hours on Monday, reaching $5.00. The company’s stock had a trading volume of 48,467 shares, compared to its average volume of 94,373. The firm has a market capitalization of $104.45 million, a price-to-earnings ratio of -5.32 and a beta of 0.97. The firm has a 50-day simple moving average of $4.60 and a 200-day simple moving average of $5.09. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38.

Institutional Investors Weigh In On Journey Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after buying an additional 12,882 shares during the last quarter. Nwam LLC bought a new stake in Journey Medical during the 3rd quarter valued at $59,000. PVG Asset Management Corp raised its holdings in Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after buying an additional 9,005 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new stake in Journey Medical during the 3rd quarter valued at $66,000. Finally, Citadel Advisors LLC bought a new stake in Journey Medical during the 4th quarter valued at $174,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.